Linyuan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Linyuan Wang has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Jianjun Zhang
School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China
15 shared publications Jianjun Zhang
School of Traditional Chinese Medicine, Beijing University of Chinese Medicine
6 shared publications- Wenting Fei
School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China
5 shared publications Chun Wang
School of traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
4 shared publicationsJinlian Liu
School of Traditional Chinese Medicine, Inner Mongolia Medical University
4 shared publicationsRuilin Lv
School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China
4 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 13, 1866695
Oral L-carnitine supplementation lowers serum uric acid and is associated with renal and intestinal urate-handling responses in hyperuricemic mice
Introduction: Hyperuricemia (HUA) is a common metabolic disorder associated with gout, renal dysfunction, and intestinal microenvironment disturbance. Impaired urate excretion is considered a major driver of sustained HUA. However, whether nutritional interventions are associated with renal and intestinal urate-handling-related responses remains unclear. This exploratory study investigated whether oral L-carnitine supplementation reduces serum uric acid levels and is accompanied by renal, intestinal, and microbiota-related changes. Methods: Male C57BL/6 mice were fed a UA/PO-supplemented diet for 12 weeks to establish the HUA model. Mice were assigned to a control group, an untreated HUA group, and L-carnitine-treated groups. Serum uric acid and renal-related biochemical indices were measured. Renal and intestinal histology, urate transporter expression, renal signaling pathways, and gut microbiota composition were evaluated to characterize hepatic urate production-related and renal–intestinal urate-handling-related responses. Results: Oral L-carnitine supplementation reduced serum uric acid levels and improved renal-related biochemical indices. It did not significantly affect hepatic XOD or ADA, indicating that the urate-lowering effect was not primarily explained by reduced hepatic urate production. In the kidney, L-carnitine restored OAT1 expression and attenuated NF-κB-related inflammatory signaling. In the intestine, it improved villus structure, increased ZO-1 and Occludin expression, and was associated with increased intestinal ABCG2 expression. Gut microbiota structure was also partially restored. Conclusion: These findings suggest that oral L-carnitine may act as a potential nutritional modulator of urate homeostasis. Its urate-lowering effect was not accompanied by detectable suppression of hepatic urate production, but was associated with renal and intestinal urate-handling-related responses. However, because standardized 24-h urinary and fecal urate excretion measurements and transporter functional assays were not performed, enhanced renal or intestinal urate excretion was not demonstrated.
- 15 September 2026
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 13, 1866695
Open AccessOral L-carnitine supplementation lowers serum uric acid and is associated with renal and intestinal urate-handling responses in hyperuricemic mice
Introduction: Hyperuricemia (HUA) is a common metabolic disorder associated with gout, renal dysfunction, and intestinal microenvironment disturbance. Impaired urate excretion is considered a major driver of sustained HUA. However, whether nutritional interventions are associated with renal and intestinal urate-handling-related responses remains unclear. This exploratory study investigated whether oral L-carnitine supplementation reduces serum uric acid levels and is accompanied by renal, intestinal, and microbiota-related changes. Methods: Male C57BL/6 mice were fed a UA/PO-supplemented diet for 12 weeks to establish the HUA model. Mice were assigned to a control group, an untreated HUA group, and L-carnitine-treated groups. Serum uric acid and renal-related biochemical indices were measured. Renal and intestinal histology, urate transporter expression, renal signaling pathways, and gut microbiota composition were evaluated to characterize hepatic urate production-related and renal–intestinal urate-handling-related responses. Results: Oral L-carnitine supplementation reduced serum uric acid levels and improved renal-related biochemical indices. It did not significantly affect hepatic XOD or ADA, indicating that the urate-lowering effect was not primarily explained by reduced hepatic urate production. In the kidney, L-carnitine restored OAT1 expression and attenuated NF-κB-related inflammatory signaling. In the intestine, it improved villus structure, increased ZO-1 and Occludin expression, and was associated with increased intestinal ABCG2 expression. Gut microbiota structure was also partially restored. Conclusion: These findings suggest that oral L-carnitine may act as a potential nutritional modulator of urate homeostasis. Its urate-lowering effect was not accompanied by detectable suppression of hepatic urate production, but was associated with renal and intestinal urate-handling-related responses. However, because standardized 24-h urinary and fecal urate excretion measurements and transporter functional assays were not performed, enhanced renal or intestinal urate excretion was not demonstrated.
- Open Access
- 17 June 2026
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 14, 1848728
An integrated annotation strategy for the phytochemical characterization of Xie-Bai-San decoction based on UPLC-Q Exactive Orbitrap HRMS, multi-database screening, and feature-based molecular networking
Introduction: Characterizing plant-derived compounds in complex botanical formulations remains challenging because of matrix complexity, structurally related analogues, and frequent isomerism. Xie-Bai-San decoction (XBSD), a traditional herbal formula composed of Cortex Mori, Cortex Lycii, and Radix et Rhizoma Glycyrrhizae, represents a complex botanical system requiring comprehensive phytochemical characterization. Methods: An integrated phytochemical annotation strategy was developed using UPLC-Q Exactive Orbitrap HRMS combined with an automated data processing workflow incorporating an in-house library, public databases, and feature-based molecular networking (FBMN). Compound characterization was further supported by reference standard validation, MS/MS spectral interpretation, literature comparison, and confidence-level assignment. Results: A total of 218 compounds were annotated or tentatively characterized in XBSD, including 80 flavonoids, 35 organic acids, 23 amides, 21 terpenoids, 17 coumarins, 8 saccharides, 6 alkaloids, 5 stilbenes, 3 cyclic peptides, and 20 other constituents. Among them, 74 compounds were reported from XBSD for the first time, and 13 compounds were unambiguously identified using authentic reference standards. Representative MS/MS fragmentation features were elucidated to guide the annotation of structurally related analogues. FBMN enabled the visual clustering of molecular families, facilitating rapid structural inference and improving confidence in analogue annotation, particularly for isomers and low-abundance compounds. Discussion: This study provides a comprehensive chemical profile of XBSD and demonstrates that the integrated UPLC-HRMS-based workflow improves the efficiency, reliability, and transparency of phytochemical annotation in complex traditional herbal formulations. The proposed strategy may serve as a practical analytical framework for the rapid characterization of structurally diverse constituents in other complex botanical systems.
- 17 June 2026
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 14, 1848728
Open AccessAn integrated annotation strategy for the phytochemical characterization of Xie-Bai-San decoction based on UPLC-Q Exactive Orbitrap HRMS, multi-database screening, and feature-based molecular networking
Introduction: Characterizing plant-derived compounds in complex botanical formulations remains challenging because of matrix complexity, structurally related analogues, and frequent isomerism. Xie-Bai-San decoction (XBSD), a traditional herbal formula composed of Cortex Mori, Cortex Lycii, and Radix et Rhizoma Glycyrrhizae, represents a complex botanical system requiring comprehensive phytochemical characterization. Methods: An integrated phytochemical annotation strategy was developed using UPLC-Q Exactive Orbitrap HRMS combined with an automated data processing workflow incorporating an in-house library, public databases, and feature-based molecular networking (FBMN). Compound characterization was further supported by reference standard validation, MS/MS spectral interpretation, literature comparison, and confidence-level assignment. Results: A total of 218 compounds were annotated or tentatively characterized in XBSD, including 80 flavonoids, 35 organic acids, 23 amides, 21 terpenoids, 17 coumarins, 8 saccharides, 6 alkaloids, 5 stilbenes, 3 cyclic peptides, and 20 other constituents. Among them, 74 compounds were reported from XBSD for the first time, and 13 compounds were unambiguously identified using authentic reference standards. Representative MS/MS fragmentation features were elucidated to guide the annotation of structurally related analogues. FBMN enabled the visual clustering of molecular families, facilitating rapid structural inference and improving confidence in analogue annotation, particularly for isomers and low-abundance compounds. Discussion: This study provides a comprehensive chemical profile of XBSD and demonstrates that the integrated UPLC-HRMS-based workflow improves the efficiency, reliability, and transparency of phytochemical annotation in complex traditional herbal formulations. The proposed strategy may serve as a practical analytical framework for the rapid characterization of structurally diverse constituents in other complex botanical systems.
- Open Access
- 4 August 2025
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 106 (2) , e70150
Inhibition Effects of Patchouli Alcohol, Carvacrol, p ‐Cymene, Eucalyptol and Their Formulations Against Influenza Virus Pneumonia Through TLR4 / NF ‐ κB / NLRP3 Signaling Pathway
As a kind of drug mostly used historically to treat epidemics, aromatic botanicals have volatile oils as active components. The study aims to evaluate the anti‐influenza viral pneumonia effects of volatile monomers patchouli alcohol (PA), carvacrol (CV), p‐ Cymene (PC), eucalyptol (EC) and their formulations from various aspects through the influenza virus A/PR/8/34 (H1N1) infection experiment in vivo and in vitro and carry out in‐depth studies on the anti‐inflammatory mechanisms. In this study, we found that all four volatile monomers mentioned above could exert antiviral effects by suppressing pulmonary viral load and lung index and improving lung lesions in mice with influenza pneumonia. In addition, elevated levels of cytokines and chemokines in the serum were suppressed, the proportion of T‐lymphocytes in the peripheral blood was altered, and antioxidative stress indices were improved, whose mechanism of action related to anti‐inflammation, possibly acting on the Toll‐Like Receptor 4/Nuclear Factor‐κB/nucleotide‐binding domain leucine‐rich repeat and pyrin domain‐containing receptor 3 (TLR4/NF‐κB/NLRP3) pathway. The study provides an experimental basis for volatile monomers and their formulations of aromatic herbs for treating influenza virus pneumonia.
- 4 August 2025
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 106 (2) , e70150
Open AccessInhibition Effects of Patchouli Alcohol, Carvacrol, p ‐Cymene, Eucalyptol and Their Formulations Against Influenza Virus Pneumonia Through TLR4 / NF ‐ κB / NLRP3 Signaling Pathway
As a kind of drug mostly used historically to treat epidemics, aromatic botanicals have volatile oils as active components. The study aims to evaluate the anti‐influenza viral pneumonia effects of volatile monomers patchouli alcohol (PA), carvacrol (CV), p‐ Cymene (PC), eucalyptol (EC) and their formulations from various aspects through the influenza virus A/PR/8/34 (H1N1) infection experiment in vivo and in vitro and carry out in‐depth studies on the anti‐inflammatory mechanisms. In this study, we found that all four volatile monomers mentioned above could exert antiviral effects by suppressing pulmonary viral load and lung index and improving lung lesions in mice with influenza pneumonia. In addition, elevated levels of cytokines and chemokines in the serum were suppressed, the proportion of T‐lymphocytes in the peripheral blood was altered, and antioxidative stress indices were improved, whose mechanism of action related to anti‐inflammation, possibly acting on the Toll‐Like Receptor 4/Nuclear Factor‐κB/nucleotide‐binding domain leucine‐rich repeat and pyrin domain‐containing receptor 3 (TLR4/NF‐κB/NLRP3) pathway. The study provides an experimental basis for volatile monomers and their formulations of aromatic herbs for treating influenza virus pneumonia.
- Open Access
- 26 March 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (4) , 468
Aromatic Molecular Compatibility Attenuates Influenza Virus-Induced Acute Lung Injury via the Lung–Gut Axis and Lipid Droplet Modulation
Background: Acute lung injury (ALI) is a major cause of death in patients with various viral pneumonias. Our team previously identified four volatile compounds from aromatic Chinese medicines. Based on molecular compatibility theory, we defined their combination as aromatic molecular compatibility (AC), though its therapeutic effects and underlying mechanisms remain unclear. Methods: This study used influenza A virus (IAV) A/PR/8/34 to construct cell and mouse models of ALI to explore AC’s protective effects against viral infection. The therapeutic effect of AC was verified by evaluating the antiviral efficacy in the mouse models, including improvements in their lung and colon inflammation, oxidative stress, and the suppression of the NLRP3 inflammasome. In addition, 16S rDNA and lipid metabolomics were used to analyze the potential therapeutic mechanisms of AC. Results: Our in vitro and in vivo studies demonstrated that AC increased the survival of the IAV-infected cells and mice, inhibited influenza virus replication and the expression of proinflammatory factors in the lung tissues, and ameliorated barrier damage in the colonic tissues. In addition, AC inhibited the expression of ROS and the NLRP3 inflammasome and improved the inflammatory cell infiltration into the lung tissues. Finally, AC effectively regulated intestinal flora disorders and lipid metabolism in the model mice, significantly reduced cholesterol and triglyceride expression, and thus reduced the abnormal accumulation of lipid droplets (LDs) after IAV infection. Conclusions: In this study, we demonstrated that AC could treat IAV-induced ALIs through multiple pathways, including antiviral and anti-inflammatory pathways and modulation of the intestinal flora and the accumulation of LDs.
- 26 March 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (4) , 468
Open AccessAromatic Molecular Compatibility Attenuates Influenza Virus-Induced Acute Lung Injury via the Lung–Gut Axis and Lipid Droplet Modulation
Background: Acute lung injury (ALI) is a major cause of death in patients with various viral pneumonias. Our team previously identified four volatile compounds from aromatic Chinese medicines. Based on molecular compatibility theory, we defined their combination as aromatic molecular compatibility (AC), though its therapeutic effects and underlying mechanisms remain unclear. Methods: This study used influenza A virus (IAV) A/PR/8/34 to construct cell and mouse models of ALI to explore AC’s protective effects against viral infection. The therapeutic effect of AC was verified by evaluating the antiviral efficacy in the mouse models, including improvements in their lung and colon inflammation, oxidative stress, and the suppression of the NLRP3 inflammasome. In addition, 16S rDNA and lipid metabolomics were used to analyze the potential therapeutic mechanisms of AC. Results: Our in vitro and in vivo studies demonstrated that AC increased the survival of the IAV-infected cells and mice, inhibited influenza virus replication and the expression of proinflammatory factors in the lung tissues, and ameliorated barrier damage in the colonic tissues. In addition, AC inhibited the expression of ROS and the NLRP3 inflammasome and improved the inflammatory cell infiltration into the lung tissues. Finally, AC effectively regulated intestinal flora disorders and lipid metabolism in the model mice, significantly reduced cholesterol and triglyceride expression, and thus reduced the abnormal accumulation of lipid droplets (LDs) after IAV infection. Conclusions: In this study, we demonstrated that AC could treat IAV-induced ALIs through multiple pathways, including antiviral and anti-inflammatory pathways and modulation of the intestinal flora and the accumulation of LDs.
- Open Access
- 7 February 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (6) , e41394
A real-world study to observe the efficacy and safety of Lutai Danshen Baishao Granules for improving melasma
Background: Traditional Chinese Medicine categorizes melasma into various syndromes, one of which is the kidney-deficiency and blood-stasis syndrome. Different Chinese medicines are used for each syndrome to achieve a personalized treatment approach, resulting in a more effective outcome. The study aimed to investigate the efficacy and safety of Lutai Danshen Baishao Granules (LDBG) in alleviating melasma and to compare the effects of LDBG in patients with and without kidney-deficiency and blood-stasis syndrome through a real-world, large-sample investigation. Methods: A multicenter, prospective, nonrandomized, observational trial was conducted from December 2021 to May 2023, recruiting 1000 female participants with melasma. After enrollment, participants were divided into Group A (kidney-deficiency and blood-stasis syndrome) and group B (non-kidney-deficiency and blood-stasis syndrome) based on the traditional Chinese medicine (TCM) syndrome scale. General physical signs, melasma indicators, Dermatology Life Quality Index, and TCM syndrome scores were recorded before and after the intervention. The long-term effectiveness was assessed 2 months after the intervention ended. Results: Following the intervention, melasma-related indicators and TCM syndrome scores were significantly lower than those before the intervention (P < .001). Compared to Group B, Group A showed a more significant reduction in the total area of melasma and the Melasma Area and Severity Index score (P < .05). The reduction in melasma area was also more pronounced in Group A (group A: 425.00 vs group B: 312.50, P < .001). Two months after the intervention, intergroup and intragroup comparisons revealed that LDBG had a long-term effect with a lower tendency for recurrence, and the long-term effect in Group A was better than in group B (P < .05). The overall incidence of adverse events during the trial was 1.2%. Conclusion: LDBG can reduce facial melasma and improve TCM syndromes, particularly in cases of melasma associated with kidney-deficiency and blood-stasis syndrome, with high safety and low risk of relapse.
- 7 February 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (6) , e41394
Open AccessA real-world study to observe the efficacy and safety of Lutai Danshen Baishao Granules for improving melasma
Background: Traditional Chinese Medicine categorizes melasma into various syndromes, one of which is the kidney-deficiency and blood-stasis syndrome. Different Chinese medicines are used for each syndrome to achieve a personalized treatment approach, resulting in a more effective outcome. The study aimed to investigate the efficacy and safety of Lutai Danshen Baishao Granules (LDBG) in alleviating melasma and to compare the effects of LDBG in patients with and without kidney-deficiency and blood-stasis syndrome through a real-world, large-sample investigation. Methods: A multicenter, prospective, nonrandomized, observational trial was conducted from December 2021 to May 2023, recruiting 1000 female participants with melasma. After enrollment, participants were divided into Group A (kidney-deficiency and blood-stasis syndrome) and group B (non-kidney-deficiency and blood-stasis syndrome) based on the traditional Chinese medicine (TCM) syndrome scale. General physical signs, melasma indicators, Dermatology Life Quality Index, and TCM syndrome scores were recorded before and after the intervention. The long-term effectiveness was assessed 2 months after the intervention ended. Results: Following the intervention, melasma-related indicators and TCM syndrome scores were significantly lower than those before the intervention (P < .001). Compared to Group B, Group A showed a more significant reduction in the total area of melasma and the Melasma Area and Severity Index score (P < .05). The reduction in melasma area was also more pronounced in Group A (group A: 425.00 vs group B: 312.50, P < .001). Two months after the intervention, intergroup and intragroup comparisons revealed that LDBG had a long-term effect with a lower tendency for recurrence, and the long-term effect in Group A was better than in group B (P < .05). The overall incidence of adverse events during the trial was 1.2%. Conclusion: LDBG can reduce facial melasma and improve TCM syndromes, particularly in cases of melasma associated with kidney-deficiency and blood-stasis syndrome, with high safety and low risk of relapse.
- Open Access
- 2 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (23) , 12967
Transcriptomic Analysis Reveals the Potential Mechanism of Cardamine circaeoides Hook.f. & Thomson in Lowering Serum Uric Acid by Reducing Inflammatory State Through CCR7 Target
Cardamine circaeoides Hook.f. & Thomson (CC) is a traditional medicinal herb with multiple biological activities. In previous studies, we have identified its serum uric acid (SUA) lowering effects and speculated that Cardamine circaeoides water extract (CCE) may exert anti-hyperuricemia effects related to its anti-inflammatory activity. This study aims to further investigate the molecular mechanism underlying these effects at the mRNA level through transcriptomic analysis, quantitative reverse transcription polymerase chain reaction (RT-qPCR), molecular docking, and Western blotting. CCE effectively reduced SUA and improved renal function in a dose-dependent manner in hyperuricemia rats. Cytokine–cytokine receptor interaction pathway was significantly altered by CCE. An additional study identified a number of genes (IL27, Inhbe, CCR7, CXCR3, IL12RB1, CXCR5, Mstn, and GDF5) as regulators of the inflammatory response. Meanwhile, three key targets (IL27, Inhbe, and CCR7) were found to be significantly expressed at the mRNA level and have strong binding affinity with 22 components, among which Kaempferol 3-sophoroside 7-glucoside, Kaempferol-3-O-sophoroside, and Quercetin 3-sophoroside 7-glucoside have strong binding activities. Following this, Western blotting showed a significant increase in CCR7 expression. Our findings indicated that CCE regulated the cytokine–cytokine receptor interaction pathway through CCR7 to reduce the inflammatory state and exert an SUA-lowering effect.
- 2 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (23) , 12967
Open AccessTranscriptomic Analysis Reveals the Potential Mechanism of Cardamine circaeoides Hook.f. & Thomson in Lowering Serum Uric Acid by Reducing Inflammatory State Through CCR7 Target
Cardamine circaeoides Hook.f. & Thomson (CC) is a traditional medicinal herb with multiple biological activities. In previous studies, we have identified its serum uric acid (SUA) lowering effects and speculated that Cardamine circaeoides water extract (CCE) may exert anti-hyperuricemia effects related to its anti-inflammatory activity. This study aims to further investigate the molecular mechanism underlying these effects at the mRNA level through transcriptomic analysis, quantitative reverse transcription polymerase chain reaction (RT-qPCR), molecular docking, and Western blotting. CCE effectively reduced SUA and improved renal function in a dose-dependent manner in hyperuricemia rats. Cytokine–cytokine receptor interaction pathway was significantly altered by CCE. An additional study identified a number of genes (IL27, Inhbe, CCR7, CXCR3, IL12RB1, CXCR5, Mstn, and GDF5) as regulators of the inflammatory response. Meanwhile, three key targets (IL27, Inhbe, and CCR7) were found to be significantly expressed at the mRNA level and have strong binding affinity with 22 components, among which Kaempferol 3-sophoroside 7-glucoside, Kaempferol-3-O-sophoroside, and Quercetin 3-sophoroside 7-glucoside have strong binding activities. Following this, Western blotting showed a significant increase in CCR7 expression. Our findings indicated that CCE regulated the cytokine–cytokine receptor interaction pathway through CCR7 to reduce the inflammatory state and exert an SUA-lowering effect.
- Open Access
- 3 April 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1298471
Boosting the immunogenicity of the CoronaVac SARS-CoV-2 inactivated vaccine with Huoxiang Suling Shuanghua Decoction: a randomized, double-blind, placebo-controlled study
Introduction: In light of the public health burden of the COVID-19 pandemic, boosting the safety and immunogenicity of COVID-19 vaccines is of great concern. Numerous Traditional Chinese medicine (TCM) preparations have shown to beneficially modulate immunity. Based on pilot experiments in mice that showed that supplementation with Huoxiang Suling Shuanghua Decoction (HSSD) significantly enhances serum anti-RBD IgG titers after inoculation with recombinant SARS-CoV-2 S-RBD protein, we conducted this randomized, double-blind, placebo-controlled clinical trial aimed to evaluate the potential immunogenicity boosting effect of oral HSSD after a third homologous immunization with Sinovac’s CoronaVac SARS-CoV-2 (CVS) inactivated vaccine.Methods: A total of 70 participants were randomly assigned (1:1 ratio) to receive a third dose of CVS vaccination and either oral placebo or oral HSSD for 7 days. Safety aspects were assessed by recording local and systemic adverse events, and by blood and urine biochemistry and liver and kidney function tests. Main outcomes evaluated included serum anti-RBD IgG titer, T lymphocyte subsets, serum IgG and IgM levels, complement components (C3 and C4), and serum cytokines (IL-6 and IFN-γ). In addition, metabolomics technology was used to analyze differential metabolite expression after supplementation with HSSD.Results: Following a third CVS vaccination, significantly increased serum anti-RBD IgG titer, reduced serum IL-6 levels, increased serum IgG, IgM, and C3 and C4 levels, and improved cellular immunity, evidenced by reduce balance deviations in the distribution of lymphocyte subsets, was observed in the HSSD group compared with the placebo group. No serious adverse events were recorded in either group. Serum metabolomics results suggested that the mechanisms by which HSSD boosted the immunogenicity of the CVS vaccine are related to differential regulation of purine metabolism, vitamin B6 metabolism, folate biosynthesis, arginine and proline metabolism, and steroid hormone biosynthesis.Conclusion: Oral HSSD boosts the immunogenicity of the CVS vaccine in young and adult individuals. This trial provides clinical reference for evaluation of TCM immunomodulators to improve the immune response to COVID-19 vaccines.
- 3 April 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1298471
Open AccessBoosting the immunogenicity of the CoronaVac SARS-CoV-2 inactivated vaccine with Huoxiang Suling Shuanghua Decoction: a randomized, double-blind, placebo-controlled study
Introduction: In light of the public health burden of the COVID-19 pandemic, boosting the safety and immunogenicity of COVID-19 vaccines is of great concern. Numerous Traditional Chinese medicine (TCM) preparations have shown to beneficially modulate immunity. Based on pilot experiments in mice that showed that supplementation with Huoxiang Suling Shuanghua Decoction (HSSD) significantly enhances serum anti-RBD IgG titers after inoculation with recombinant SARS-CoV-2 S-RBD protein, we conducted this randomized, double-blind, placebo-controlled clinical trial aimed to evaluate the potential immunogenicity boosting effect of oral HSSD after a third homologous immunization with Sinovac’s CoronaVac SARS-CoV-2 (CVS) inactivated vaccine.Methods: A total of 70 participants were randomly assigned (1:1 ratio) to receive a third dose of CVS vaccination and either oral placebo or oral HSSD for 7 days. Safety aspects were assessed by recording local and systemic adverse events, and by blood and urine biochemistry and liver and kidney function tests. Main outcomes evaluated included serum anti-RBD IgG titer, T lymphocyte subsets, serum IgG and IgM levels, complement components (C3 and C4), and serum cytokines (IL-6 and IFN-γ). In addition, metabolomics technology was used to analyze differential metabolite expression after supplementation with HSSD.Results: Following a third CVS vaccination, significantly increased serum anti-RBD IgG titer, reduced serum IL-6 levels, increased serum IgG, IgM, and C3 and C4 levels, and improved cellular immunity, evidenced by reduce balance deviations in the distribution of lymphocyte subsets, was observed in the HSSD group compared with the placebo group. No serious adverse events were recorded in either group. Serum metabolomics results suggested that the mechanisms by which HSSD boosted the immunogenicity of the CVS vaccine are related to differential regulation of purine metabolism, vitamin B6 metabolism, folate biosynthesis, arginine and proline metabolism, and steroid hormone biosynthesis.Conclusion: Oral HSSD boosts the immunogenicity of the CVS vaccine in young and adult individuals. This trial provides clinical reference for evaluation of TCM immunomodulators to improve the immune response to COVID-19 vaccines.
- Open Access
- 2 November 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1281411
Integrative metabolomic and network pharmacological analysis reveals potential mechanisms of Cardamine circaeoides Hook.f. & Thomson in alleviating potassium oxonate-induced asymptomatic hyperuricemia in rats
Cardamine circaeoides Hook.f. & Thomson (CC), a herb of the genus Cardamine (family Brassicaceae), has a rich historical usage in China for both culinary and medicinal purposes. It is distinguished by its remarkable ability to hyperaccumulate selenium (Se). CC has demonstrated efficacy in the prevention of metabolic disorders. However, investigations into the effects of CC on asymptomatic hyperuricemia remain scarce. The objective of this study is to elucidate the mechanism by which CC aqueous extract (CCE) exerts its anti-hyperuricemic effects on asymptomatic hyperuricemic rats induced by potassium oxonate (PO) by integrating metabolomics and network pharmacological analysis. Asymptomatic hyperuricemia was induced by feeding rats with PO (1000 mg/kg) and CCE (0.75, 1.5, or 3 g/kg) once daily for 30 days. Various parameters, including body weight, uric acid (UA) levels, histopathology of renal tissue, and inflammatory factors (IL-1β, IL-6, IL-8, and TNF-α) were assessed. Subsequently, metabolomic analysis of kidney tissues was conducted to explore the effects of CCE on renal metabolites and the related pathways. Furthermore, network pharmacology was employed to explicate the mechanism of action of CCE components identified through UPLC-Q-TOF-MS analysis. Finally, metabolomic and network-pharmacology analyses were performed to predict crucial genes dysregulated in the disease model and rescued by CCE, which were then subjected to verification by RT-qPCR. The findings revealed that CCE significantly inhibited the UA levels from the 21st day to the 30th day. Moreover, CCE exhibited significant inhibition of IL-1β, IL-6, IL-8, and TNF-α levels in renal tissues. The dysregulation of 18 metabolites and the tyrosine, pyrimidine, cysteine, methionine, sphingolipid, and histidine metabolism pathways was prevented by CCE treatment. A joint analysis of targets predicted using the network pharmacology approach and the differential metabolites found in metabolics predicted 8 genes as potential targets of CCE, and 3 of them (PNP gene, JUN gene, and ADA gene) were verified at the mRNA level by RT-qPCR. We conclude that CCE has anti-hyperuricemia effects and alleviates renal inflammation in a rat model of hyperuricemia, and these efficacies are associated with the reversal of increased ADA, PNP, and JUN mRNA expression in renal tissues.
- 2 November 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1281411
Open AccessIntegrative metabolomic and network pharmacological analysis reveals potential mechanisms of Cardamine circaeoides Hook.f. & Thomson in alleviating potassium oxonate-induced asymptomatic hyperuricemia in rats
Cardamine circaeoides Hook.f. & Thomson (CC), a herb of the genus Cardamine (family Brassicaceae), has a rich historical usage in China for both culinary and medicinal purposes. It is distinguished by its remarkable ability to hyperaccumulate selenium (Se). CC has demonstrated efficacy in the prevention of metabolic disorders. However, investigations into the effects of CC on asymptomatic hyperuricemia remain scarce. The objective of this study is to elucidate the mechanism by which CC aqueous extract (CCE) exerts its anti-hyperuricemic effects on asymptomatic hyperuricemic rats induced by potassium oxonate (PO) by integrating metabolomics and network pharmacological analysis. Asymptomatic hyperuricemia was induced by feeding rats with PO (1000 mg/kg) and CCE (0.75, 1.5, or 3 g/kg) once daily for 30 days. Various parameters, including body weight, uric acid (UA) levels, histopathology of renal tissue, and inflammatory factors (IL-1β, IL-6, IL-8, and TNF-α) were assessed. Subsequently, metabolomic analysis of kidney tissues was conducted to explore the effects of CCE on renal metabolites and the related pathways. Furthermore, network pharmacology was employed to explicate the mechanism of action of CCE components identified through UPLC-Q-TOF-MS analysis. Finally, metabolomic and network-pharmacology analyses were performed to predict crucial genes dysregulated in the disease model and rescued by CCE, which were then subjected to verification by RT-qPCR. The findings revealed that CCE significantly inhibited the UA levels from the 21st day to the 30th day. Moreover, CCE exhibited significant inhibition of IL-1β, IL-6, IL-8, and TNF-α levels in renal tissues. The dysregulation of 18 metabolites and the tyrosine, pyrimidine, cysteine, methionine, sphingolipid, and histidine metabolism pathways was prevented by CCE treatment. A joint analysis of targets predicted using the network pharmacology approach and the differential metabolites found in metabolics predicted 8 genes as potential targets of CCE, and 3 of them (PNP gene, JUN gene, and ADA gene) were verified at the mRNA level by RT-qPCR. We conclude that CCE has anti-hyperuricemia effects and alleviates renal inflammation in a rat model of hyperuricemia, and these efficacies are associated with the reversal of increased ADA, PNP, and JUN mRNA expression in renal tissues.
- Open Access
- 7 March 2023
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 14, 1111886
Improvement influenza vaccine immune responses with traditional Chinese medicine and its active ingredients
The current influenza vaccines are unable to provide effective protection in many cases, like influenza viruses strain antigenic drift or shift, and the influenza continues to cause significant annual morbidity and mortality. Improving the immune response to influenza vaccination is an unmet need. Traditional Chinese medicine (TCM) and its active ingredients are commonly known to have immunomodulatory properties. We therefore compared influenza vaccination alone or formulated with Astragali Radix (Huangqi in Chinese), and several representative ingredients of TCM, including lentinan (polysaccharide), panax notoginseng saponins (saponin), breviscapine (flavone), andrographolide (terpenoid), and a Chinese herbal compound (kangai) for their potential to enhance immune responses to influenza vaccine in mice. We found that all these TCM-adjuvants were able to increase hemagglutination inhibition (HAI) antibody titers, splenocyte proliferation, splenic T cell differentiation, bone marrow dendritic cell maturity, and both Th1 and Th2 cytokine secretion of influenza vaccine to varying degrees, and that had the characteristics of no excessive inflammatory responses and bidirectional regulation simultaneously. Taken together, our findings show that Astragali Radix exerts a more comprehensive effect on vaccine immunity, on both innate and adaptive immunity. The effects of lentinan and andrographolide on adaptive immunity were more significant, while the effects of breviscapine on innate immunity were stronger, and the other two TCM adjuvants were weaker. As the first report of a comprehensive evaluation of TCM adjuvants in influenza vaccines, the results suggest that TCM and their active ingredients are good candidates for enhancing the immune response of influenza vaccines, and that suitable TCMs can be selected based on the adjuvant requirements of different vaccines.
- 7 March 2023
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 14, 1111886
Open AccessImprovement influenza vaccine immune responses with traditional Chinese medicine and its active ingredients
The current influenza vaccines are unable to provide effective protection in many cases, like influenza viruses strain antigenic drift or shift, and the influenza continues to cause significant annual morbidity and mortality. Improving the immune response to influenza vaccination is an unmet need. Traditional Chinese medicine (TCM) and its active ingredients are commonly known to have immunomodulatory properties. We therefore compared influenza vaccination alone or formulated with Astragali Radix (Huangqi in Chinese), and several representative ingredients of TCM, including lentinan (polysaccharide), panax notoginseng saponins (saponin), breviscapine (flavone), andrographolide (terpenoid), and a Chinese herbal compound (kangai) for their potential to enhance immune responses to influenza vaccine in mice. We found that all these TCM-adjuvants were able to increase hemagglutination inhibition (HAI) antibody titers, splenocyte proliferation, splenic T cell differentiation, bone marrow dendritic cell maturity, and both Th1 and Th2 cytokine secretion of influenza vaccine to varying degrees, and that had the characteristics of no excessive inflammatory responses and bidirectional regulation simultaneously. Taken together, our findings show that Astragali Radix exerts a more comprehensive effect on vaccine immunity, on both innate and adaptive immunity. The effects of lentinan and andrographolide on adaptive immunity were more significant, while the effects of breviscapine on innate immunity were stronger, and the other two TCM adjuvants were weaker. As the first report of a comprehensive evaluation of TCM adjuvants in influenza vaccines, the results suggest that TCM and their active ingredients are good candidates for enhancing the immune response of influenza vaccines, and that suitable TCMs can be selected based on the adjuvant requirements of different vaccines.
- Open Access
- 16 February 2023
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 234, 123635
Bidirectional and persistent immunomodulation of Astragalus polysaccharide as an adjuvant of influenza and recombinant SARS-CoV-2 vaccine
- 16 February 2023
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 234, 123635
Open AccessBidirectional and persistent immunomodulation of Astragalus polysaccharide as an adjuvant of influenza and recombinant SARS-CoV-2 vaccine